Navigation Links
YM BioSciences Closes Public Offering of Common Shares
Date:12/17/2010

r of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and an
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that executives from ... the month of September.  , ... Rodman & Renshaw,s 17th Annual Global Investment Conference on ... the St. Regis Hotel in New York ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual list ... as number 1,361 in growth for the three years through 2014. Being named to ... privately held organizations in the country. , “We are thrilled to make the ...
(Date:8/26/2015)... KS (PRWEB) , ... August 26, 2015 , ... ... Biologic Solutions, announces today that a second US laboratory is to open in ... accordance with the continued partnership and long-term growth of research and development through ...
(Date:8/26/2015)...  The Diabetes Research Institute (DRI), a Center ... School of Medicine, announced today that the first ... the first time a novel transplant technique for ... Phase I/II study builds upon decades of progress ... first step toward the development of the DRI ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... ,D+CAF(TM) Caffeine Test Strips, to Know for Sure, Studies show ... ... levels of caffeine, MONROVIA, Calif., Nov. 12 Ever wonder ... know for sure,with new D+CAF, the first ever do-it-yourself caffeine test strip ...
... Can Streamline the Procurement Process using,SciQuest,s Solutions, ... Inc., the global leader,empowering enterprises to realize ... formation of a strategic alliance with QIAGEN, ... Through the alliance,both companies will work together ...
... GAITHERSBURG, Md., Nov. 12 MaxCyte, Inc.,the pioneer ... it will be hosting a live discussion with ... assays for drug discovery.,The discussion is open to ... on,Thursday, November 13th from 2:00-3:00EST., One of ...
Cached Biology Technology:Is Your Decaf Really Decaf? 2SciQuest Announces Strategic Alliance with QIAGEN 2SciQuest Announces Strategic Alliance with QIAGEN 3SciQuest Announces Strategic Alliance with QIAGEN 4MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... OXFORD, CT ., Aug. 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... wallet, announces it has joined The Smart Card Alliance ... the Smart Card Alliance and the Smart Card Alliance ... and visibility to industry peers and thought leaders promoting ...
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... known to repair their tissues effortlessly, but can this capacity ... the Stem Cell Program at Boston Children,s Hospital suggests that ... is active in embryonic stem cells, researchers were able to ... tissues in a mouse model. The study also ...
... more than doubled in children and tripled in adolescents ... according to the Centers for Disease Control and Prevention. ... health concern since overweight and obese youth are at ... for adults. These new pediatric diseases include type-2 diabetes, ...
... A recent prospective, randomized, placebo-controlled clinical trial reports that ... a group of male veterans with epilepsy who were ... in Epilepsia , a journal of the International ... may help to prevent new vertebral fractures when taken ...
Cached Biology News:Researchers regrow hair, cartilage, bone, soft tissues 2For obese teen girls, aerobic exercise may trump resistance training in health benefits 2For obese teen girls, aerobic exercise may trump resistance training in health benefits 3Calcium and vitamin D improve bone density in patients taking antiepileptic drugs 2
...
... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
...
... Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
Biology Products: